QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 

   

 

Posting date: April 19, 2005
This Article
* Reprint (PDF)
* HTML Version
* Appendix
* Submit a response to this article
* View responses
* Alert me when this article is cited
* Alert me when eLetters are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Stuart, B.
* Articles by Chauncey, D.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Stuart, B.
* Articles by Chauncey, D.
Health Affairs, 10.1377/hlthaff.w5.167
Copyright © 2005 by Project HOPE


Web Exclusives

Assessing The Impact Of Coverage Gaps In The Medicare Part D Drug Benefit

Bruce Stuart 1*, Linda Simoni-Wastila 2, Danielle Chauncey 3

1 Bruce Stuart is a professor and director of the Peter Lamy Center on Drug Therapy and Aging, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, in Baltimore.
2 Linda Simoni-Wastila is an associate professor at the center.
3 Danielle Chauncey is a doctoral student at the School of Pharmacy.

*Corresponding author.

  Abstract

The new Medicare Part D drug benefit contains major coverage gaps for people who spend moderate to high amounts on prescription drugs who qualify only for the standard coverage. To help policymakers understand the impact such gaps will have on those affected, we studied a representative sample of Medicare beneficiaries with naturally occurring prescription benefit gaps between 1998 and 2000 using data from the Medicare Current Beneficiary Survey. Our findings suggest that discontinuities in drug benefits result in sizable reductions in medication use and spending, which is magnified in people with common chronic illnesses.

Key Words: Business Of Health, Consumer Issues, Elderly, Health Reform, Insurance Coverage, Medicare, Pharmaceuticals, Health Spending


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
JAMAHome page
J. M. Madden, A. J. Graves, F. Zhang, A. S. Adams, B. A. Briesacher, D. Ross-Degnan, J. H. Gurwitz, M. Pierre-Jacques, D. G. Safran, G. S. Adler, et al.
Cost-Related Medication Nonadherence and Spending on Basic Needs Following Implementation of Medicare Part D
JAMA, April 23, 2008; 299(16): 1922 - 1928.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
G. F. Joyce, D. P. Goldman, P. Karaca-Mandic, and Y. Zheng
Pharmacy Benefit Caps And The Chronically Ill
Health Aff., September 1, 2007; 26(5): 1333 - 1344.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
J. Graham and J. Hu
The Risk-Benefit Balance In The United States: Who Decides?
Health Aff., May 1, 2007; 26(3): 625 - 635.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Assessing the Analysis Gaps: Strengths of the Medicare Drug Benefit
Bill Thomas
Health Affairs, 23 Sep 2005 [Full text]
Re: Assessing the Analysis Gaps: Strengths of the Medicare Drug Benefit
Bruce C. Stuart, et al.
Health Affairs, 28 Sep 2005 [Full text]


Home | Current Issue | Archives | Topic Collections | Search | Blog | Subscribe | Contact Us | Help

© 2001-2005 Project HOPE–The People-to-People Organization
Terms and Policies